BOSTON SCIENTIFIC CORP
BSXNYSEHealthcare · Surgical & Medical Instruments & Apparatus · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $20.07B | $16.75B | $14.24B | $12.68B | $11.89B | $9.91B |
| Operating income | $3.61B | $2.60B | $2.34B | $1.65B | $1.20B | −$80.0M |
| Net income | $2.89B | $1.85B | $1.59B | $698.0M | $1.04B | −$82.0M |
| Total assets | $43.67B | $39.40B | $35.14B | $32.47B | $32.23B | $30.78B |
| Total liabilities | — | — | — | — | — | — |
| Equity | $24.23B | $21.77B | $19.28B | $17.57B | $16.62B | $15.33B |
| EPS (diluted) | $1.94 | $1.25 | $1.07 | $0.45 | $0.69 | $-0.08 |
| Shares out. | 1.48B | 1.47B | 1.43B | 1.43B | 1.42B | 1.40B |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- 18.0%
- Net margin
- 14.4%
- Return on equity
- 11.9%
- Return on assets
- 6.6%
- Return on capital (ROCE)
- 9.4%
- Liabilities / assets
- —
- Debt / equity
- —
- Book value / share
- $16.42
- Revenue growth (YoY)
- 19.9%
- Net income growth (YoY)
- 56.7%
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Accruals / assets
- −3.8%clean
- Piotroski F-Score
- 7/8strong
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 4 good- Operating margin is positive
- Revenue is growing year-over-year
- Positive operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 3Active Not Recruitingreadout ~2023-10-02A Clinical Trial to Assess the Agent Paclitaxel Coated PTCA Balloon Catheter for the Treatment of Subjects With In-Stent Restenosis (ISR)
- Phase 4Active Not Recruitingreadout ~2025-07-31Ultrasound-facilitated, Catheter-directed, Thrombolysis in Intermediate-high Risk Pulmonary Embolism
- Phase 2Active Not Recruitingreadout ~2027-06TheraSphere With Durvalumab and Tremelimumab for HCC
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Fmr LlcPassive (13G)May 6, 2026
- Vanguard Capital Management LlcPassive (13G)Apr 29, 2026
- Vanguard Group IncPassive (13G)Mar 26, 2026
- Blackrock, Inc.Passive (13G)Apr 17, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 31.4M | 1.8 | +9.7% |
| Apr 30, 2026 | 28.6M | 1.4 | +11.8% |
| Apr 15, 2026 | 25.6M | 1.8 | +8.9% |
| Mar 31, 2026 | 23.5M | 1.4 | -7.5% |
| Mar 13, 2026 | 25.4M | 2.0 | -3.1% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Other material eventMay 18, 2026
- Other material eventMay 18, 2026
- Amended charter or bylaws · Shareholder voteMay 5, 2026
- Results of operationsApr 22, 2026
- Other material eventMar 30, 2026
- Entered a material agreement · Terminated a material agreement · New financial obligationFeb 26, 2026
- Director / officer change · Regulation FD disclosure · Other material eventFeb 23, 2026
- Director / officer changeFeb 5, 2026
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (5)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.